TY - JOUR
T1 - New-Generation High-Potency and Designer Antibodies
T2 - Role in HIV-1 Treatment
AU - Gama, Lucio
AU - Koup, Richard A.
N1 - Publisher Copyright:
© This is a work of the U.S. Government and is not subject to copyright protection in the United States.
PY - 2018/1/29
Y1 - 2018/1/29
N2 - Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in both preventive and therapeutic modalities. Multiple bNAbs have been isolated, characterized, and assessed in vitro and in vivo, but no single antibody appears to possess the breadth and potency that may be needed if it is to be used in the treatment of HIV-1 infection. With the technological advances of the past decades, novel and more effective bNAbs have been identified or engineered for higher neutralizing potency, greater breadth, and increased serum half-life. In this review, we discuss the development of a new generation of anti-HIV-1 bNAbs and their potential to be used clinically for treatment and prevention of HIV-1 infection.
AB - Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in both preventive and therapeutic modalities. Multiple bNAbs have been isolated, characterized, and assessed in vitro and in vivo, but no single antibody appears to possess the breadth and potency that may be needed if it is to be used in the treatment of HIV-1 infection. With the technological advances of the past decades, novel and more effective bNAbs have been identified or engineered for higher neutralizing potency, greater breadth, and increased serum half-life. In this review, we discuss the development of a new generation of anti-HIV-1 bNAbs and their potential to be used clinically for treatment and prevention of HIV-1 infection.
KW - Broadly neutralizing antibodies (bNAbs)
KW - HIV-1
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85041720660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041720660&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-061016-041032
DO - 10.1146/annurev-med-061016-041032
M3 - Review article
C2 - 29029583
AN - SCOPUS:85041720660
SN - 0066-4219
VL - 69
SP - 409
EP - 419
JO - Annual review of medicine
JF - Annual review of medicine
ER -